v3.21.2
Consolidated Statements of Earnings and Comprehensive Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2019
Net sales $ 931,032 $ 738,691 $ 714,006
Cost of sales 298,182 255,497 240,515
Gross margin 632,850 483,194 473,491
Operating expenses:      
Selling, general and administrative 324,951 260,583 264,359
Research and development 70,603 65,192 62,413
Total operating expenses 395,554 325,775 326,772
Operating income 237,296 157,419 146,719
Other income (expense):      
Interest expense (13,952) (19,197) (21,705)
Interest income 473 605 569
Other non-operating income (expense), net (75,642) 137,650 (13,568)
Total other income (expense), net (89,121) 119,058 (34,704)
Earnings before income taxes 148,175 276,477 112,015
Income taxes (benefit) 8,590 47,181 15,943
Net earnings, including noncontrolling interest 139,585 229,296 96,072
Net earnings (loss) attributable to noncontrolling interest (825) 0 0
Net earnings attributable to Bio-Techne 140,410 229,296 96,072
Other comprehensive income (loss):      
Foreign currency translation adjustments 32,951 (9,963) (4,487)
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8. 7,060 (3,715) (9,537)
Other comprehensive income (loss) 40,011 (13,678) (14,024)
Other comprehensive income (loss) attributable to noncontrolling interest 103 0 0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total 39,908 (13,678) (14,024)
Comprehensive income attributable to Bio-Techne $ 180,318 $ 215,618 $ 82,048
Earnings per share:      
Basic (in dollars per share) $ 3.62 $ 6.00 $ 2.54
Diluted (in dollars per share) $ 3.47 $ 5.82 $ 2.47
Weighted average common shares outstanding:      
Basic (in shares) 38,747 38,201 37,781
Diluted (in shares) 40,483 39,401 38,892

Source